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ABSTRACT 
 
Secular and Longitudinal Trends in Body Weight in a Large Population of Veterans, 2000-2014  
 
By 
 
Margery Jean Burrage Tamas 
 
December 9, 2015 
 
 
INTRODUCTION: The prevalence of obesity is increasing in the United States and globally, and 
impacts many aspects of health. To understand the contribution of body weight to chronic 
diseases such as diabetes, it is necessary to characterize secular and longitudinal weight trends 
prior to evaluating the weight effects that may result from medical interventions. The cross-
sectional National Health and Nutrition Examination Survey (NHANES) indicates that mean 
body weight in the adult population increased from 152 lb (69 kg) to 181 lb (82 kg) between 1959 
and 2008. However, there are no previously published studies on secular or longitudinal weight 
trends in a veteran population. 
 
OBJECTIVES: The purpose of this study is to describe secular and longitudinal trends in body 
weight for a large population of male and female individuals with and without diabetes in the 
Veterans Administration (VA) healthcare system, the largest integrated healthcare system in the 
United States.  
 
METHODS: Retrospective observational analysis of data from VA facilities throughout the 
United States, in patients who had at least 4 outpatient visits within any consecutive 4-year 
interval during 2000–2014. The dataset included men and women with and without type 2 
diabetes. The primary outcomes were longitudinal trends in body weight stratified by birth cohort, 
sex, and diabetes status. 
 
RESULTS: A total of 4,680,735 unique patients, 1,666,346 with diabetes, were included in the 
analysis. Regressions were performed on the patient-level data and segmented by birth cohort. A 
total of 176,034,543 weight observations were included in the analysis, with a median of 15 to 36 
weight observations per patient in individuals without diabetes, and a median of 22 to 49 weight 
observations in individuals with diabetes across birth cohorts. In the year 2000, the y-intercept for 
the regression equations indicated a mean body weight for men without diabetes of 188 lb (85 
kg), for women without diabetes of 166 lb (75 kg), for men with diabetes of 213 lb (97 kg), and 
for women with diabetes of 195 lb (88 kg). Secular trends in body weight during the study period 
had median linear increases of 0.53 lb/y (0.24 kg/y) in men with diabetes, 0.50 lb/y (0.23 kg/y) in 
women with diabetes, 0.53 lb/y (0.24 kg/y) in men without diabetes, and 0.86 lb/y (0.39 kg/y) 
among women without diabetes, respectively. In cohorts born before 1940, body weight 
decreased. In the cohorts born between 1940-1949, body weight was stable. In all cohorts born 
after 1950, body weight increased. Across birth cohorts, the rate of weight increase accelerated 
from older to younger groups, with higher rates in the groups with diabetes than in the groups 
without diabetes: β2 = 0.0260 lb2/y (0.01179 kg2/y) in men without diabetes, 0.0398 lb2/y 
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(0.01805 kg2/y) in men with diabetes, 0.0127 lb2/y (0.00576 kg2/y) in women without diabetes, 
and 0.0895 lb2/y (0.04060 kg2/y) in women with diabetes. 
 
CONCLUSIONS: This is the first report of secular and longitudinal weight trends in a large, 
contemporary veteran population that includes both men and women. Consistent with findings 
from the Normative Aging Study, a longitudinal study of male veterans from the northeastern 
United States, weight changes varied from decreases among the oldest birth cohorts to increases 
in the youngest birth cohorts. Secular changes in body weight by birth cohort were consistent with 
the patterns reported in the Global Burden of Disease Study. The rate of weight change is 
accelerated in all younger birth cohorts relative to all older birth cohorts, with the highest rates in 
women with diabetes. Further analyses of this dataset are recommended to elucidate clinical 
characteristics associated with longitudinal weight change among individuals with and without 
diabetes in the veteran population. 
 
 
INDEX WORDS: veterans, diabetes, body weight, longitudinal trends, descriptive statistics, 
epidemiology  
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INTRODUCTION 
 
1.1 Background 
1.1.1 Secular and longitudinal trends in body weight 
Obesity is a risk factor for many chronic diseases, including diabetes (Ng et al, 2014; 
Fryar et al, 2014; Samanic et al, 2004). Globally, the prevalence of obesity is increasing (Ng et al, 
2014). In the United States, data from the National Health and Nutrition Examination Survey 
(NHANES) shows that the prevalence of overweight, defined by a body mass index (BMI) of 25 
kg/m2 or more, declined between 1960-2012, but the prevalence of obesity (BMI ≥ 30 kg/m2) and 
extreme obesity (BMI ≥ 40 kg/m2) has generally increased in both men and women (Fryar et al, 
2014).  
The Normative Aging Study was a prospective cohort study of 2280 healthy male veterans 
from the Boston, Massachusetts area recruited in 1961-1970, ranging in age from 30 to 78 years 
at baseline, and for whom 15-year outcomes for body weight and obesity have been reported 
(Grinker et al, 1995). The Veterans Administration (VA) healthcare system is the largest 
integrated healthcare system in the United States, and has a very large electronic medical records 
database that has been used extensively in epidemiological research in obesity and diabetes (e.g., 
Gebregziabher et al, 2011; Jackson et al, 2015; Olson et al, 2015; Samanic et al, 2004; Thorpe et 
al, 2015; Tseng et al, 2014). However, there are no previously published studies on secular or 
longitudinal weight trends in a large, contemporary veteran population.  
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1.1.2 Body weight and diabetes 
Diabetes is a prevalent chronic disease in the United States, with an estimated population 
prevalence of 12% to 14% (Menke et al, 2015). Type 2 diabetes is vastly more prevalent than type 
1 diabetes: the best estimate of type 1 prevalence in the noninstitutionalized civilian population is 
0.26% to 0.34% (Menke et al, 2013). Diabetes has a prevalence of approximately 25% within the 
VA healthcare system (US Department of Veterans Affairs, 2015).  
Among patients with diabetes, interventions to improve glycemic control are often 
measured by their effects on glycated hemoglobin (A1C) (Inzucchi et al, 2015). However, A1C 
reduction is generally associated with weight gain (Horton et al, 2010; Fonseca et al, 2013; 
Abraira et al, 2009).  Hence, the effects of interventions for diabetes need to be separated from 
secular trends toward weight increase that have been observed in individuals with and without 
diabetes (Ng et al, 2014; Morgan et al, 2012; Krieger et al, 2013; Fryar et al, 2014).  
Insulin is always used to treat type 1 diabetes, but many different classes of medications 
are used to treat type 2 diabetes (Menke et al, 2013; Inzucchi et al, 2015). Type 2 diabetes 
mellitus is characterized by chronic hyperglycemia due to insulin resistance coupled with 
progressive pancreatic beta-cell failure (Kahn, 2003). Because of the progression of beta-cell loss, 
exogenous insulin therapy eventually becomes necessary for many patients with type 2 diabetes 
(Khunti et al, 2015; Inzucchi et al, 2015; Zinman, 1989). 
Current treatment algorithms for the management of type 2 diabetes from the American 
Diabetes Association (ADA) (Inzucchi et al, 2015) recommend insulin throughout the progression 
of the disease. The ADA recommends initiating treatment with metformin, an oral agent, unless 
A1C is severely elevated (A1C ≥ 9%), in which case insulin is the preferred agent (Inzucchi et al, 
2015). In type 2 diabetes, insulin is also recommended for use in combination with other 
antihyperglycemic agents (Inzucchi et al, 2015).  
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Insulin use is generally associated with weight gain, and is considered more likely than 
other antihyperglycemic medications to be associated with weight gain > 5% (Horton et al, 2010; 
Morgan et al, 2012). As insulin is the most efficacious agent for reducing A1C (Inzucchi et al, 
2015), there is a need to differentiate an insulin-specific effect on body weight from effects 
associated with reducing A1C (Huizinga et al, 2008). Other investigators have noted that weight 
gain of approximately 2 kg for every 1% reduction in A1C follows the initiation of insulin or 
sulfonylureas (UKPDS 28, UKPDS 33). Avoiding weight gain with intensification of glycemic 
control is of great practical interest to clinicians and to individuals with type 2 diabetes. 
Other factors that may affect body weight in individuals with diabetes are the effects of 
certain other medications for comorbid conditions (Kushner & Ryan, 2014), hypoglycemia 
(Sanders et al, 2006; Seaquist et al, 2013), smoking (Fonseca et al, 2013; Grinker et al, 1995), and 
lifestyle interventions (Look AHEAD Study Group, 2014; Jackson et al, 2015). 
1.2 Aims 
This thesis represents the first portion of a larger study that is intended to assess changes 
in body weight as a function of changes in glycemic control with insulin therapy, accounting for 
the effects of hypoglycemia, other medications known to affect body weight, smoking, and 
lifestyle interventions, all while controlling for secular trends in body weight. A retrospective 
study of 6032 individuals in general practice in the United Kingdom found that 1 year after 
initiating insulin therapy, body weight increased by 2.2 kg and A1C decreased by 1.4%, but the 
overall range of weight change was –60 kg  to 60 kg, and the range of A1C change was –15% to 
15% (Owen et al, 2010). Other than noting that patients using premixed insulin therapy exhibited 
the greatest weight gain, the authors offer no explanation for the extreme weight changes.  
 Of the 4 aims of the larger proposed study, this thesis mainly addresses Aim 1. 
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1.2.1 Aim 1 
To compare longitudinal trends in body weight among individuals with and without type 2 
diabetes. 
 
1.2.2 Aim 2 
To determine the relationship between changes in body weight and changes in A1C among 
individuals with type 2 diabetes, according to whether they initiated insulin or some other 
antihyperglycemic medication. 
 
1.2.3 Aim 3 
To determine whether participation in the MOVE! lifestyle intervention alters the relationship 
between change in body weight and change in A1C among the individuals with type 2 diabetes. 
 
1.2.4 Aim 4 
To determine whether hypoglycemia alters the relationship between change in body weight and 
change in A1C among the individuals with type 2 diabetes. 
  
1.3 Hypotheses  
The hypotheses listed below represent all of the hypotheses for the larger, overall study. 
Data presented in this thesis are limited to longitudinal and secular weight trends in men and 
women with and without diabetes for hypothesis 1, and A1C distribution and smoking status for 
hypothesis 2. 
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1.3.1 Hypothesis 1 
Body weight will increase with time in all groups (e.g., individuals with and without diabetes, 
men and women). 
1.3.2 Hypothesis 2 
For a given change in A1C, patients initiating insulin therapy will have a greater change in body 
weight than patients who initiate one of the noninsulin therapies (i.e., the change in body weight 
per 1-unit change in A1C will differ depending on whether insulin or a noninsulin treatment is 
initiated). 
1.3.3 Hypothesis 3 
Participants in the VA lifestyle intervention MOVE! will have less weight gain per unit change in 
A1C than nonparticipants. 
1.3.4 Hypothesis 4 
Individuals with hypoglycemia will gain more weight than individuals without hypoglycemia. 
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REVIEW OF THE LITERATURE 
      
2.1 Population Trends in Body Weight 
In terms of the first goal of the larger study (Aim 1), it is important to elucidate secular 
and longitudinal trends in weight change according to sex and birth cohort. 
2.1.1 Global trends and trends outside the United States 
The Global Burden of Disease Study found that in developed countries, the prevalence of 
obesity increases with age, and that the rate of increase is higher in younger birth cohorts than in 
older cohorts (Ng et al, 2014). Both the prevalence and the rate of development of obesity with 
age are higher in women (Ng et al, 2014). Morgan et al (2012), studying the UK general practice 
population, found that body weight increased from 1995-2010 in adult men and women with or 
without diabetes.  
2.1.2 Trends in the United States 
Ogden et al (2015) estimated the crude prevalence of obesity among adults in the United 
States during 2011-2014 at 36.5%. Prevalence was higher among women (38.3%) than among 
men (34.3%) (Ogden et al, 2015). Similar patterns of obesity by age were seen in both men and 
women, with the highest rates among individuals aged 40-59 years, the second-highest rates 
among individuals aged 60 years and over, and the lowest rates among individuals aged 20-39 
years (Ogden et al, 2015). In terms of race and ethnicity, among adults, non-Hispanic blacks had 
the highest rate of obesity (48.1%), followed by Hispanic individuals (42.5%), non-Hispanic 
whites (34.5%), and non-Hispanic Asians (11.7%) (Ogden et al, 2015). Analyses of data collected 
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from the NHANES shows that the mean body weight of the population in the United States 
increased from 1959-2008 (Krieger et al, 2013).  
Individuals with diabetes are even more likely to be overweight or obese than individuals 
who do not have diabetes (CDC, 2004). In NHANES 1999-2002, 30.5% of the population aged ≥ 
20 years was overweight or obese, but 85.2% of adults with diagnosed diabetes were overweight 
or obese, although women with diabetes were somewhat less likely than men with diabetes to be 
overweight or obese (84.2% vs 86.3%, respectively) (CDC, 2004). Mexican individuals with 
diabetes had the highest prevalence of obesity (86.9%), followed by non-Hispanic blacks with 
diabetes (86.1%), and non-Hispanic whites with diabetes (85.9%) (CDC, 2004). The prevalence 
of obesity and overweight was higher overall and in every subgroup in 1999-2002 than in 
NHANES III (1988-1994) (CDC, 2004).  
2.1.3 Trends in veteran populations 
In the Normative Aging Study previously described, among the 867 men with data 
available for 15 years, the authors state that major secular differences were observed, with the 
younger cohorts exhibiting higher body weight at the same ages as men from the older cohorts 
(Grinker et al, 1995). The mean ± SD change in body weight over 15 years among participants 
aged 30-34 years at baseline was 2.65 ± 6.54 kg, whereas the participants aged ≥ 60 years lost 
weight (–4.11 ± 4.99 kg) (Grinker et al, 1995). The coefficient of the first-order linear regression 
equation was –0.469 kg/y, P < .001 for trend (Grinker et al, 1995). Similar patterns of results 
were found for trends in BMI with birth cohort and with time: BMI increased by 1.03 ± 2.13 
kg/m2 in the participants aged 30-34 years at baseline, but the change was –0.69 ± 1.78 kg/m2 in 
the participants aged ≥ 60 years at baseline, P < .001 for trend (Grinker et al, 1995). 
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Smoking cessation was identified as an important contributor to weight gain (Grinker et 
al, 1995). A 3-way classification scheme was used to identify smoking status: never smoked or 
quit before the study (65%), always smoked (16%), or quit during the study (18%) (Grinker et al, 
1995). Individuals who quit during the study had the greatest BMI increase, approximately 1.55 
kg/m2, while those who always smoked had the least BMI increase, approximately 0.4 kg/m2, and 
the third group had an intermediate BMI increase of approximately 0.7 kg/m2 (Grinker et al, 
1995). 
Accordingly, the current study describes trends in body weight in men and women with 
and without diabetes.  
2.2 Weight Change and Insulin Initiation  
In terms of the goals of the larger study (Aims 2-4), it is important to distinguish 
treatment-associated weight gain, as may occur with insulin therapy, from secular trends in 
weight change according to sex and birth cohort. 
2.2.1 Weight Change and Insulin Initiation--Randomized Controlled Trials With Weight Change as 
a Primary Endpoint 
After searching PubMed and the references cited in the meta-analyses by Pontiroli (2011 
and 2012), only 4 small RCTs (Barratt et al [2008], Jacob et al [2007], Yki-Jarvinen et al [1999], 
and Makimattila et al [1999]) were identified which investigated insulin initiation in T2DM with 
weight change as a primary endpoint. Makimattila et al (1999) published a small RCT (N = 26) 
which included a graph of weight change versus change in fasting glucose over 1 year. Mean 
weight gains of 3.8 kg and 7.5 kg were reported in the 2 arms of the trial, but 2 outlier weight 
gains (17 kg and 22 kg) were not discussed.  
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2.2.2 Weight Change and Insulin Initiation--Other Randomized Controlled Trials 
Weight change is commonly measured in clinical trials of insulin therapy, and the reported 
range of weight gain is large.  
A meta-analysis of weight change data from 143 insulin arms of 67 randomized controlled 
trials of 12-52 weeks duration (Pontiroli et al [2011] and Pontiroli et al [2012]) found that insulin 
initiation was associated with an annualized weight gain of 4.3 ± 2.74 kg (mean ± sd; range: –2.76 
to 14.7 kg). Of the study arms included in these papers, only 4 demonstrated a mean weight loss. 
The largest (N = 12,443) and longest RCT of insulin therapy, the ORIGIN trial (2012), 
found that insulin treatment resulted in a median weight gain of 1.6 kg over 6.2 years compared 
with 0.5 kg median weight loss in the standard care group. 
2.2.3 Weight Change and Insulin Initiation--Observational Studies 
Few studies report the range or distribution of change in body weight after insulin 
initiation. A study of the UK Health Improvement Network database by Owen et al (2010) found 
that weight increased 2.2 kg (P < .001) and A1C was reduced by 1.4% (P < .001) in the first year 
after insulin initiation. However, a scatter plot included in this publication indicated that many of 
the 6032 patients analyzed gained or lost more than 20 kg within the first year of insulin initiation 
(Owen et al, 2010). The authors noted that patients using premixed insulins were more likely to 
gain weight than patients using other types of insulin regimens, but offered no further comment 
on the extreme range of weight change observed in routine clinical general practice (range: ≈ −60 
kg to ≈ 60 kg).  
Feldstein et al (2008) studied a population of patients in the Kaiser Permanente health 
system and distinguished 4 different weight trajectories in the first year following the diagnosis of 
type 2 diabetes: high stable weight, lower stable weight, weight gain, and weight loss. For this 
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population, 18.3% followed the high stable weight trajectory, 54.1% followed the lower stable 
weight trajectory, 16.0% followed the weight gain trajectory, and 11.6% followed the weight loss 
trajectory (Feldstein et al, 2008). About 75% of the individuals following the weight loss 
trajectory had A1C < 7% at 1 year, whereas only 44.3% of the individuals following the weight 
gain trajectory had A1C < 7% at 1 year (Feldstein et al, 2008). Contrasting results were also seen 
among individuals with A1C ≥ 9% at 1 year, comprising 2.7% of those on the weight loss 
trajectory, and 16% of those on the weight gain trajectory (Feldstein et al, 2008).  
The 12-nation, observational CREDIT study reported that 1 year after insulin initiation in 
2179 patients with type 2 diabetes, the mean weight gain was 1.78 kg (median 2.0 kg), and 24% 
of participants gained ≥ 5 kg (Balkau et al, 2015). The distribution of weight gain and loss was 
symmetrically distributed around the mean, with a range of weight change varying from −20 kg to 
22 kg (Balkau et al, 2015). CREDIT found notable country-by-country variation in the mean 
weight gain, from as little as 0.95 kg in Germany to as much as 4.26 kg in Portugal (Balkau et al, 
2015). After adjusting for recruitment center, only a higher baseline A1C, a lower baseline BMI, 
and a higher insulin dose at baseline and at 1 year predicted weight gain; no relationship between 
weight change and change in A1C was found on multivariate analysis (Balkau et al, 2015). 
CREDIT did not include a control group. 
A similar range of weight change was found by van Dieren et al (2012) in a post hoc 
analysis of ADVANCE (N = 11,140). This RCT was not an insulin therapy trial per se, but a trial 
of intensive versus standard glycemic control, suggesting that extreme weight change may be 
more a function of glycemic control rather than insulin therapy specifically. Both Balkau and van 
Dieren published histograms of individual-level weight changes, and in both papers, the 
distribution of weight change appears symmetrical around the mean.  
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A small (N = 122) prospective observational study by Jansen et al (2011) prospectively 
followed patients initiating insulin therapy for 3 years and found that only 12% of the weight gain 
in the first 9 months after insulin initiation was explained by changes in glycemic control. A 
prospective 1-year study of 74 patients by Jansen et al (2014) found that weight change ranged 
from –6 kg to 19 kg, with 71% of patients gaining weight and 29% maintaining or losing weight. 
The authors recommended initiating insulin at a low dose and gradually uptitrating to avoid 
weight gain.  
 
2.3 Weight Change and Intensive Diabetes Management 
Several large randomized trials of intensive diabetes therapy individuals with type 2 
diabetes have generated longitudinal data on body weight by treatment group, e.g., VADT, 
ACCORD, and ADVANCE (Abraira et al, 2009; Fonseca et al, 2013; van Dieren et al, 2012). In 
the VADT (Abraira et al, 2009) and the ACCORD (Fonseca et al, 2013) studies, higher weight 
gain was observed in the intensive treatment arms. By contrast, body weight remained stable in 
the intensive treatment arm of ADVANCE (van Dieren et al, 2012). The ADVANCE trial 
demonstrated a symmetric distribution of weight gain and loss about the mean with intensive or 
standard glycemic control, with the distribution skewed toward greater weight gain in the 
intensive control group (van Dieren et al, 2012). 
2.4 Weight Change and Hypoglycemia  
There are at least two mechanisms by which hypoglycemia might cause weight gain, and 
both have been demonstrated in animal models: hypoglycemia-induced overfeeding (e.g., Sanders 
et al [2006]) and reduced physical activity following repeated episodes of severe hypoglycemia 
(McNay et al, 2013). Hypoglycemia as a factor that might modify the relationship between 
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changes in glycemia and weight with insulin therapy in humans with type 2 diabetes has not 
previously been studied, although a meta-analysis by Pontiroli et al (2011) showed that mean 
weight gain was positively correlated with the proportion of individuals reporting hypoglycemia.  
Cardiovascular risk factors are more prevalent in the VA population both before and after 
diagnosis of diabetes (Olson et al, 2015). Current treatment guidelines for hypertension in type 2 
diabetes recommend angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor 
blockers (ARBs) as first-line therapy (Fox et al, 2015). Interestingly, a common genetic 
polymorphism (rs1799752) increases the risk of severe hypoglycemia with ACE inhibitor usage 
(Gard, 2010). The deletion (D) allele of the ACE gene is estimated to occur in about 55% of the 
population (Gard, 2010). In the Fremantle Diabetes Study, individuals with the DD genotype 
were at 2-fold higher risk of severe hypoglycemia (Davis et al, 2011). Although ACE genotype 
does not appear to affect blood pressure response to ACE inhibitors, these agents may precipitate 
hypoglycemia in patients with diabetes (Jarred & Kennedy, 2010; Morris et al, 1997). 
Antihypertensive medications are widely used in the VA population (Olson et al, 2015; Jackson et 
al, 2015; Thorpe et al, 2015). 
Within the VA Healthcare System, older patients with multiple comorbidities are often 
maintained at levels of glycemic control which increase the risk of hypoglycemia (Tseng et al, 
2014). Comorbid dementia further increases the risk of hypoglycemia in older veterans with type 
2 diabetes (Thorpe et al, 2015). 
2.5 Weight Change and Other Medications 
Many types of drugs, including many antihyperglycemic agents, affect body weight 
(Kushner & Ryan, 2014). Antihyperglycemic agents associated with weight gain include insulin, 
sulfonylureas, and thiazolidinediones (Kushner & Ryan, 2014; Inzucchi et al, 2015). Dipeptidyl 
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peptidase-4 (DPP-4) inhibitors are considered weight-neutral; metformin is considered weight-
neutral to weight sparing, and the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and 
sodium glucose cotransporter-2 (SGLT2) inhibitors are considered to promote weight loss 
(Inzucchi et al, 2015). Current treatment guidelines for type 2 diabetes include explicit 
consideration of their effects on body weight, but do not consider the effects of concomitant 
medications that may be prescribed for common comorbidities of diabetes, such as depression 
(Dumbreck et al, 2015).  
Individuals with type 2 diabetes are more likely to have depression than individuals who 
do not have type 2 diabetes (Mezuk et al, 2015), and are therefore at higher risk of exposure to 
antidepressant drugs. Some antidepressants (e.g., amitriptyline, imipramine, nortriptyline, 
paroxetine), some anticonvulsants (e.g., valproate), and steroid hormones (e.g., glucocorticoids) 
are associated with weight gain (Kushner & Ryan, 2014). By contrast, other antidepressants (e.g., 
fluoxetine, sertraline, bupropion), and other anticonvulsants (e.g., topiramate, lamotrigine) are 
associated with weight loss (Kushner & Ryan, 2014). A recent study of the US Medicare 
population found that 2.5% of individuals with comorbid type 2 diabetes and depression were 
prescribed tricyclic antidepressants (Lorgunpai et al, 2014), potentially increasing their risk of 
weight gain. 
Within the VA system, off-label use of antipsychotic medication is common among 
patients with posttraumatic stress disorder, minor depression, major depression, anxiety, and 
dementia; these drugs are also used for their on-label indications of schizophrenia or bipolar 
disorder (Leslie et al, 2009). Several neuroleptic agents (e.g., haloperidol, olanzapine, quetiapine, 
risperidone) are associated with pronounced weight gain (Kushner & Ryan, 2014). The 
concomitant use of rosiglitazone, a thiazolidinedione used to improve insulin sensitivity and 
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reduce blood glucose levels, and olanzapine, an antipsychotic agent, was associated with a weight 
gain of 3.2 ± 4.5 kg over 12 weeks in a small randomized controlled trial of individuals with 
schizophrenia (Baptista et al, 2009).  
Thus, any study of longitudinal weight outcomes in patients with type 2 diabetes needs to 
consider the possibility that the results will be confounded by concomitant medications.  
2.6 Weight Change and Smoking Status 
Van Dieren et al (2012) identified smoking status as one of the primary patient 
characteristics predicting weight gain with insulin initiation in the ADVANCE trial; the other 
factors were age, ethnicity, and baseline A1C. The use of insulin in combination with 
thiazolidinediones was the most important treatment-related predictor (van Dieren et al, 2012). 
Similarly, in the ACCORD trial, Fonseca et al (2013) found that smoking status was strongly 
associated with weight gain, with the highest gains among current smokers. 
Feldstein et al (2008) found that quitting smoking was one of the factors significantly 
associated with weight gain in the first year after diagnosis of type 2 diabetes; the other factors 
associated with weight gain were sulfonylurea use or not seeing a nutritionist. Insulin use was 
more common among those who gained weight (2.3%) than those who lost weight (1.1%), but not 
significantly so (P = .062) (Feldstein et al, 2008). 
Smoking cessation was also identified as an important contributor to weight gain in the 
Normative Aging Study (Grinker et al, 1995). A 3-way classification scheme was used to identify 
smoking status: never smoked or quit before the study (65%), always smoked (16%), or quit 
during the study (18%) (Grinker et al, 1995). Individuals who quit during the study had the 
greatest BMI increase, approximately 1.55 kg/m2, while those who always smoked had the least 
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BMI increase, approximately 0.4 kg/m2, and the third group had an intermediate BMI increase of 
approximately 0.7 kg/m2 (Grinker et al, 1995). 
2.7 Efficacy of Lifestyle Interventions to Mitigate Weight Gain With Interventions 
for Diabetes 
In people with type 2 diabetes, a number of behavioral and psychosocial factors may 
contribute to overeating, and consequent weight gain, including depression and fatalism (e.g., 
TODAY Study Group, 2011; Walker et al, 2012). Limited data are available on which to base 
recommendations for lifestyle interventions to mitigate weight gain in patients with diabetes, 
whether or not they are treated with insulin therapy (Look AHEAD Research Group, 2014; 
Jackson et al, 2015; Russell-Jones & Khan, 2007). Increasing physical activity and reducing 
caloric intake are often recommended to patients with type 2 diabetes to mitigate weight gain, but 
it is unclear whether general recommendations concerning the type of activity and intensity 
needed to maintain or lose weight also apply when insulin is initiated. 
Barratt (N = 50) compared an intensive self-management education intervention with 
standard education, and found that over 6 months, participants in the standard group gained a 
mean 4.6 kg but that participants in the intensive group lost a mean 0.6 kg.  
The Look AHEAD study demonstrated that both intensive lifestyle intervention and 
diabetes self-management resulted in beneficial weight loss in a population with diabetes (Look 
AHEAD Research Group, 2014). With regard to the VA population, previous research has shown 
that participation in the MOVE! lifestyle change program was associated with weight loss, but its 
efficacy in the subgroup of participants with diabetes at baseline (23% of the study population) 
have not been reported separately from the overall results (Jackson et al, 2015). It would be of 
interest to know whether the VA’s MOVE! lifestyle change program, already implemented 
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throughout the VA system, mitigates weight gain following insulin initiation (Jackson et al, 
2015). 
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METHODS AND PROCEDURES 
 
3.1 Context of Study  
The Department of Veteran Affairs Clinical Data Warehouses (CDW) databases were 
interrogated and selected data analyzed on the VA Informatics and Computing Infrastructure 
(VINCI) platform. These data were used to assess secular and longitudinal trends in body weight 
in men and women with and without diabetes. In the future, these data will be used to compare 
the change in body weight and change in A1C after the initiation of insulin and other 
antihyperglycemic medications in type 2 diabetes, then determine whether this relationship is 
altered by participation in the MOVE! lifestyle intervention or by hypoglycemia, smoking status, 
or other medications that may affect body weight. The data were obtained from the Institutional 
Review Board-approved data repository, “VA Diabetes Related Epidemiological Analyses” eIRB 
#66117.  
No prior studies of longitudinal and secular weight trends in a large, contemporary VA 
population have been published. 
3.2 Data Selection for Hypothesis 1 
In the VA CDW, demographic data, health factor data (e.g., smoking status), primary care 
study visit data, medication data, and laboratory measurements are all stored separately and 
indexed by various patient identification numbers, including a nationally unique patient 
identification code number, identified in this study as PatientICN. Datasets for analysis are 
assembled from CDW components through SQL queries and various sorting and merging 
operations in SAS, as indicated in Figure 3.1a. The CDW files were searched for patients with or 
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without diabetes who had at least one measurement of body weight (and BMI) during primary 
care visits within each of 4 consecutive calendar years during 2000-2014, hereafter referred to as 
“the study period.” For each patient included in the dataset, demographic information such as age, 
sex, race, ethnicity, and income was requested, as well as clinical data such as body weight and 
smoking status.  
Weight observations are customarily recorded in English units of measurement in the VA 
healthcare system. Weight observations were selected according to a 2-step process. In the first 
step, weight observations outside the range 0-1000 lb were excluded to eliminate invalid data. 
Weight observations at the extremes of the measurement range may result from disease processes 
atypical of those seen in the majority of patients with obesity and/or diabetes. Analyses based on 
extreme outliers may not be generalizable to other outpatient populations with obesity and/or 
diabetes. Accordingly, in a second step, individual weight observations were excluded if they 
were below 80 lb (36.4 kg) or greater than 600 lb (272.7 kg); 0.09% of observations were less 
than 80 lb, and fewer than 0.01% were more than 600 lb. 
Concordant with the methods used in other Atlanta VA research (e.g., Olson et al, 2015; 
Jackson et al, 2015), patients were classified as having diabetes if they had at least one use of 
ICD-9 code of 250.xx in conjunction with an outpatient visit with a primary care attending, if they 
had any two uses of the 250.xx ICD-9 codes, or if they had been prescribed an antihyperglycemic 
medication at any time during the study period. The peak incidence of type 1 diabetes occurs 
between 5-14 years of age, so individuals diagnosed with diabetes between the ages of 25-85 
years are more likely to have type 2 diabetes than type 1 diabetes (Lawrence et al, 2014). 
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Patients with diabetes who had at least 4 measurements of A1C and body weight were 
identified. At least 1 A1C measurement in each of 4 consecutive calendar years was required for 
patients with diabetes to be included in the dataset.  
Individuals with at least 4 weight measurements but who did not satisfy the criteria for 
diabetes were considered to be without diabetes. No inclusion criteria pertaining to A1C 
measurements were applied to these individuals. 
Race was classified using substring searches on the raw race variable. Any use of “white” 
was classified as white, any use of “black” was classified as black, any use of “asia” was 
classified as other, any use of “native” was classified as other, any use of “unknown” was 
classified as unknown.  
Primary analyses were performed on all available weight observations of the patients who 
were aged 25-85 years at any time during the study period. Birth years outside the range 1915-
1984 were excluded. A total of 176,034,543 weight observations were included in the primary 
analysis. 
3.3 Data Selection for Hypotheses 2-4 
 Although this thesis deals primarily with Hypothesis 1, some progress was made in terms 
of data selection needed to address Hypotheses 2-4. Data for A1C and smoking status have 
already been pulled and partly analyzed. No other data have been pulled or prepared for analysis. 
Data selection procedures for hypotheses 2-4 are summarized in Figure 3.1b.  
3.3.1 Data selection completed 
A1C observations were obtained from the CDW laboratory measurements file. All A1C 
observations for the unique patients with diabetes who met the criteria for primary care visits and 
weight observations from 2000-2014 were obtained. A1C observations are customarily recorded 
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in percent in the VA healthcare system. A1C observations outside the range 0%-100% are 
meaningless, while those at the extremes of the measurement range may result from disease 
processes atypical of those seen in the majority of patients with diabetes. A 2-step procedure was 
used to select A1C values. In the first step, A1C values outside the range 0%-100% were 
excluded. Analyses based on extreme outliers may not be generalizable to other outpatient 
populations with diabetes. Accordingly, in a second step, A1C observations were excluded if they 
were below 4% or above 20%; 0.03% of observations were less than 4%, fewer than 0.001% were 
more than 20%. This yielded 30,769,962 A1C observations for analysis.  
Smoking status was obtained from the CDW health factors file. Smoking status 
observations were obtained from 4,723,383 unique individuals with and without diabetes who met 
the criteria for primary care visits and weight observations from 2000-2014. Patients were 
classified by the most recently reported smoking status unless it was contradicted by previous 
status reports. Smoking status was considered current if they reported current in the most recent 
visit. For all other statuses, the previous statuses were reviewed, and patients were classified 
according to a hierarchy, in which former smokers included anyone who previously reported 
current or former tobacco use, and nonsmokers included only individuals who consistently 
reported tobacco nonuse. All other patterns of responses were classified as unknown, or missing, 
if null.  
3.3.2 Data selection methods recommended for future analyses 
Medication data is stored in a separate file in the CDW and will be obtained for each 
unique individual in the dataset. Antihyperglycemic medication use will be assessed for each 
unique agent in classes HS501 and HS502. Initiation of an antihyperglycemic drug will be 
considered to have occurred if no prescriptions of the drug of interest occur in the first 2 
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consecutive calendar years, but occur in both the third and fourth calendar year. Elements of this 
study plan are similar to those described in other research published by investigators at the 
Atlanta VA Medical Center, e.g., Olson et al (2015). It may also be desirable to classify agents 
using the scheme suggested by Thorpe et al (2015), which was also performed in a VA population 
(insulin only, insulin + other agents, noninsulin agents, no agents). In addition to 
antihyperglycemic medications, other medications associated with a risk of weight loss or weight 
gain will be assessed, possibly using the same methodology as Jackson et al (2015). Alternatively, 
a detailed list of medications associated with weight gain and weight loss could be compiled from 
the literature and prescribing information. 
Data files for the MOVE! participants are recorded in a file at the Atlanta VA Medical 
Center. Participation in MOVE! will be coded in categories (e.g., none, any, intense-and-
sustained) as per Jackson et al (2015).  
Diagnostic codes will be used to identify patients with hypoglycemia. Hypoglycemia will 
be defined as any use of the 251.x ICD-9 codes (Seaquist et al, 2013).  While many patients with 
type 2 diabetes have episodes of hypoglycemia where the 251.x code is not used, the total number 
of 251.x codes will be counted to approximate the number of hypoglycemic episodes which 
reached a clinical threshold of concern as shown by the use of the code. 
Descriptive statistics (including density plots of weight change vs A1C change by 
antihyperglycemic medication in groups with type 2 diabetes), and the distribution of weight 
change for each type of antihyperglycemic medication, will be obtained.  
Changes in body weight over time in the insulin groups, noninsulin groups, and 
nondiabetic controls will be assessed with using generalized estimating equations (GEE) or 
generalized linear mixed modeling (GLMM), as desirable or necessary, so that any cluster effects 
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by facility can be properly ascertained, and repeated measures accounted for. The final selection 
of analytical procedures will be made in consultation with a statistician.  
The relationships between change in A1C and change in body weight according to 
MOVE! participation status, hypoglycemia status, age, sex, race/ethnicity, facility, smoking 
status, and use of other medications that may influence weight as additional factors modifying the 
relationship between change in A1C and change in body weight will be assessed with a suitable 
statistical technique. 
 
3.4 Statistical Analysis 
3.4.1 Statistical Analysis for Hypothesis 1 
Frequency counts and distributions of the number of unique patients by diabetes status, 
sex, race, and birth cohort were obtained using PROC FREQ. Mean, standard deviation, median, 
interquartile range, minimum, and maximum values of age were calculated using PROC MEANS. 
Frequency counts of the weight observations and distributions by diabetes status, sex, 
race, and birth cohort were obtained using PROC FREQ. Mean, standard deviation, median, 
interquartile range, minimum, and maximum values of body weight by study year were calculated 
using PROC MEANS, and selected results graphed in SAS or Excel. From these data, secular 
trends in body weight were obtained in Excel. Linear regression and correlation were performed 
in Excel and the results graphed.  
Longitudinal changes in mean body weight for all of the patients were plotted. To 
ascertain general trends in the data, PROC SGPLOT with penalized b-splines (PBSPLINE option) 
for mean body weight by birth year across individuals were calculated from all available weight 
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observations. These data were stratified by birth cohort, sex, and diabetes status. Each birth cohort 
consisted of a nonoverlapping 5-year interval between 1915-1984. 
Most statistical calculations and selected graphs were performed using SAS version 9.4 
(Cary, NC, USA). Other selected graphs, linear regression, and correlation were performed using 
Excel (Microsoft, Redmond, WA, USA). Chi square analyses and unpaired t-tests of the baseline 
data were performed using an online calculator (http://www.quantpsy.org/chisq/chisq.htm and 
http://www.graphpad.com/quickcalcs/ttest1.cfm?Format=SD). Conversion of correlation 
coefficients to P-values was performed with an online calculator (http://www.danielsoper.com/ 
statcalc3/calc.aspx?id=44). Statistical tests were two-sided and performed at a 5% level of 
significance. 
Of note, none of the analyses performed for this thesis used techniques such as generalized 
estimating equations (GEE) or other methods that account for the autocorrelation that occurs with 
repeated measures, since all such methods are unavailable in the VA’s current implementation of 
SAS 9.4. 
All statistical analyses for weight were performed in pounds. Results have been reported 
in pounds and in kilograms. A conversion factor of 2.2046 lb/kg was used and results rounded to 
2-4 decimal places for weight measurements and regression coefficients.  
3.4.2 Statistical Analyses of Hypotheses 2-4 
Descriptive statistics for the A1C data were obtained, including the mean, standard 
deviation, median, interquartile range, and distribution of A1C values using PROC MEANS and 
the histogram option in PROC SGPLOT.  
Frequency counts of smoking status were obtained and a pie chart was graphed in Excel. 
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There are two statistical techniques that may be helpful in determining the extent to which 
body weight is influenced by changes in A1C. The first is generalized estimating equations 
(GEE). GEE can handle continuous, discrete, and count variables all in the same model, and 
handles repeated measures. GEE is available in SAS through PROC GENMOD. Alternatively, 
generalized linear mixed models (GLMM) could be used if it is necessary to allow a subset of the 
regression coefficients to vary randomly from one individual to another. In SAS, GLMM can be 
invoked through PROC GLIMMIX. 
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RESULTS 
 
 4.1 Descriptive Statistics 
Demographic characteristics of the study population are shown in Table 4.1. A total of 
4.68 million patients are included in the dataset, and 35.6% have diabetes. Consistent with the VA 
population, males (92.06%) and whites (78.49%) constitute the majority of patients. Individuals 
with diabetes are significantly older than individuals without diabetes (P < .0001). In terms of 
race categories, whites are the oldest and blacks are the youngest groups. The distribution of 
unique patients by race, sex, and diabetes status is shown in Figure 4.1. The number of 
individuals within each of the 16 subgroups ranges from 79,517 for females of unknown race with 
diabetes to 2.235 million for males of white race without diabetes.  The distribution of unique 
patients by birth year is shown in Figure 4.2. The birth years appear to follow a bimodal 
distribution, with a primary peak at 1947, and a secondary peak at 1932.  
A total of 12 consecutive overlapping 4-year time periods are included within the 15-year 
study window (e.g., 2000-2003, 2001-2004, 2002-2005, … 2011-2014). The mean number of data 
intervals per veteran was 5.76 ± 3.59 intervals, corresponding to an average of about 8 years of 
longitudinal data per veteran. 
The proportion of the study population with and without diabetes, by birth cohort and sex, 
is shown in Table 4.2. The proportion with diabetes ranges from 5% to 40%, with peak 
prevalence in the 1940-1944 cohort. 
The distribution of weight observations by frequency are shown in Figure 4.3. For 
purposes of illustration, frequencies > 300 observations/patient have been omitted from the figure 
but were retained for analysis. Heaping is observed at approximately every fourth frequency. This 
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may be related to the large number of patients with diabetes in this dataset, many of whom may 
have a regularly scheduled primary care visit every 3 months consistent with current standard of 
care. Patients without diabetes may be followed less regularly. Weight observation frequencies 
for subgroups in the study population are shown in Figure 4.4. There are a total of 176,034,543 
weight observations for the entire dataset. The highest median number of weight observations 
occurs in the birth cohorts from 1950-1959, as shown in Figure 4.5. Although the females with 
diabetes represent the smallest demographic group, the median number of weight observations is 
higher for this group than from any other, but the maximum number of weight observations is 
highest in the males with diabetes. The median number of weight observations was higher for 
patients with diabetes than without diabetes. Some subgroups in some birth cohorts had more than 
1000 weight observations (7 of 14 cohorts of females with diabetes, 12 of 14 cohorts of males 
with diabetes, 4 of 14 cohorts of females without diabetes, and 14 of 14 cohorts of males without 
diabetes). The median number of weight observations for females with diabetes ranged from 37-
49 observations/person across birth cohorts; corresponding statistics for males with diabetes, 
females without diabetes, and males without diabetes were 22-41, 21-36, and 15-28 
observations/person, respectively. 
Summary weight statistics by study year, sex, and diabetes status are shown in Tables 4.2-
4.5.  
 4.2 Secular Trends in Body Weight by Birth Cohort 
 Secular trends in mean body weight are shown in Figure 4.6. During the study period, 
median body weight was consistently highest in men with diabetes, followed by women with 
diabetes, men without diabetes, and women without diabetes. Body weight increased linearly in 
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all groups during the study period. Regression coefficients for secular weight trends over the 
study period are shown in Table 4.7.  
The distribution of weight observations in all groups were heavily skewed, with a wider 
range of values for the observations above the 75th percentile than the range of values below the 
25th percentile, as shown in Figure 4.7. These graphs were generated using PROC SGPANEL 
using the VBOX option, which plots the minimum, maximum, mean, median, 25th and 75th 
percentiles, and outliers, according to the SAS online documentation. Peak weights in all groups 
were at or near the upper boundary allowed value for a valid weight observation, 600 lb (272.16 
kg); conversely, minimum weights in all groups were at the lower boundary allowed for valid 
weight observations, 80 lb (36.29 kg). These findings suggest that the 80-600 lb weight range 
may be too restrictive to capture the full range of weight variation in the VA population.   
Regression equation coefficients for the mean and median for each subgroup by sex and 
diabetes status are similar, and are shown in Table 4.2.  
Further stratification by diabetes status and race was attempted, but only the 1915-1919 
cohort was small enough to analyze in this manner in SAS 9.4. The results are shown in Figure 
4.8. All weight trends are similar across race categories and diabetes status.  
4.3 Longitudinal Trends in Body Weight by Birth Cohort 
 Penalized b-splines (spaghetti plots) were fit to mean values of the longitudinal data for 
each patient for the first 100,000 observations in the entire dataset (attempts to fit the entire 
dataset exceeded available resources). In contrast to the secular trends in mean body weight, the 
mean longitudinal weight was nearly unchanged during 2000-2014 (data not shown). To rule out 
the possibility that longitudinal weight trends in some birth cohorts were cancelling out the trends 
in other birth cohorts, the data were segmented into 5-year cohorts and plotted separately. 
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Representative spline fits of the mean body weight with 95% CIs for the 1915-1919, 1945-1949, 
and 1975-1979 cohorts are shown in Figure 4.9. The spline fits show distinctive linear changes in 
mean body weight following the same patterns as the secular trend, with decreasing body weight 
in all cohorts born before 1940, nearly stable body weight in all cohorts born during 1940-1949, 
and increasing body weight in all cohorts born since 1950.  
Comparing median body weight at the beginning and ending of the study period within 
each birth cohort, the progressive changes in the magnitude and slope of the weight change for the 
2000 and 2014 timepoints by birth cohort are shown in Figure 4.10. These differences have been 
replotted as trajectories of the estimated rate of change in median body weight across birth 
cohorts in Figure 4.11.  The trajectories show a highly significant acceleration of body weight 
change from the oldest to the youngest cohorts in all subgroups by diabetes status and sex (range 
of R2: 0.9517 to 0.9881, all P < .0001) across the study window, as shown in Table 4.8 and Figure 
4.11b. 
4.4 A1C Results 
A total of 30,769,962 A1C observations in the range 4%-20% were measured in the 
1,666,346 patients with diabetes during the 2000-2014 study period. Frequency counts of A1C 
were obtained and a cumulative probability plot was graphed (Figure 3.2). A total of 14.35% of 
patients had A1C < 6%, 49.73% had A1C < 7%, and 73.8% had A1C < 8%. 
4.5 Smoking Status 
Smoking status was obtained for 4,723,383 patients with and without diabetes, which 
includes patients with birth year before 1915 and after 1984. Using the most logical smoking 
status classification algorithm developed for this thesis, in which the most recent smoking status 
was used unless it was contradicted by previously obtained codes, 19% of individuals in the 
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dataset were current smokers, 58% were former smokers, 19% were never smokers, and 4% had 
unknown smoking status.  
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DISCUSSION AND CONCLUSION 
 
5.1 Discussion of Research Questions  
5.1.1 Secular and weight trends 
The slopes of the secular trends in body weight over the 15-year period from 2000-2014 
reported in this study (Figure 4.5) were similar to those reported by Morgan et al (2012) during 
1995-2010, although the baseline weight was approximately 10 kg higher in all subgroups in this 
study than in Morgan et al. In the current study, the group with the highest mean body weight was 
the males with diabetes, and the group with the lowest mean body weight was the females without 
diabetes. However, Morgan et al (2012) found that prevalent and incident females with diabetes 
had lower mean body weight than the males without diabetes. In the current study, females with 
diabetes had higher average body weight than males without diabetes.  
Obesity prevalence was not calculated in the current study, since the research aims were to 
assess trends in weight, not BMI. In terms of the larger goals of this study, interventions for type 
2 diabetes that affect weight will be explored further. Any potential effects of interventions for 
type 2 diabetes on height (the other component of BMI) are not foreseen as targets of analysis.  
Selecting weight trends for analysis reduces the ease with which results from the current 
study can be compared with those of population surveys such as NHANES, which typically 
reports outcomes in terms of BMI. Nevertheless, some NHANES analyses do report body weight 
outcomes. The secular trends in body weight in the current study were somewhat similar to those 
observed in NHANES during 2005-2008 and reported by Krieger et al (2013). Both studies found 
population-wide linear increases in body weight. 
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An important finding of the current study is that younger birth cohorts had more rapid 
increases in body weight during the study period than did older birth cohorts. Accelerated weight 
gain as a function of younger birth cohort is also consistent with the findings reported by Ng et al 
(2014) in the Global Burden of Disease Study. 
The longitudinal pattern of decreasing body weight in older age groups and increasing 
body weight in younger age groups was previously described by Grinker et al (1995) in the 
Normative Aging Study, a longitudinal cohort study of more than 2000 men residing in the 
Boston, Massachusetts metropolitan area. It is unclear whether the statistical techniques used by 
these investigators to report longitudinal changes in body weight corrected for repeated measures.  
Further analysis of data collected from a 646-member subgroup of the Normative Aging 
Study cohort was performed by Burmaster & Murray (1998). Using a single value of weight for 
each unique individual in the subgroup, they applied splines fit by LOESS regression to the 
natural logarithm of body weight as a function of age. Their results show a gradual decrease in 
ln(weight) from age 50 to age 80. These data are normally distributed, with an ordinary least-
squares regression equation with a slope of 0.144 and a y-intercept of 4.410 (R2 = .996). Using a 
single value per participant avoids the analytical difficulties associated with repeated measures. 
Comparisons between the Normative Aging Study and the current study are facilitated by 
the facts that both were 15-year studies that divided participants according to 5-year birth cohorts, 
and the same boundaries were used for each age cohort (Grinker et al, 1995). The subgroup of 
men without diabetes in the current study was used for comparisons with the participants in the 
Normative Aging Study, as that is the most nearly comparable subgroup. At study baseline, 
overall body weight was approximately 10 kg higher in the current study than in the Normative 
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Aging Study, but the slopes of the trend lines are similar across birth cohorts, as shown in Figure 
5.1a.  
Longitudinal trends in body weight were also reported in the Normative Aging Study 
(Grinker et al, 1995). Graphs comparing longitudinal trends in body weight over 15 years in the 
Normative Aging Study and the current study are shown in Figure 5.1b. Both graphs are plotted 
to the same scale to facilitate visual comparison. The slopes of graphs by birth cohort follow the 
same general patterns with age in both studies, but are accentuated in the current study. Baseline 
weights are consistently higher, and the magnitude of the change in body weight (slope) is 
consistently larger in the current study. 
5.1.2 Discussion of A1C 
Individualized glycemic goals represent the current standard of care in type 2 diabetes 
(Inzucchi et al, 2015). The ADA has a general glycemic target of A1C < 7% for most patients, but 
notes that a stricter target of A1C < 6% may be appropriate for patients with long life 
expectancies, short disease duration, no comorbidities or vascular complications, and excellent 
self-management capabilities. A more relaxed target of A1C < 8% may be appropriate for patients 
with shorter life expectancies, long disease duration, multiple comorbidities, advanced vascular 
complications, and limited self-management capabilities. In the current study, a total of 14.35% of 
patients had A1C < 6%, 49.73% had A1C < 7%, and 73.8% had A1C < 8%. In a VA study of a 
veteran population aged ≥ 75 years, with renal impairment or a diagnosis of cognitive impairment 
or dementia (N = 652,738), 9.0% of patients had A1C < 6%, 28.6% had A1C < 7%, and 58.4% 
had A1C < 8% (Tseng et al, 2014). 
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5.1.3 Discussion of Smoking Status 
 Numerous inconsistencies were observed relative to smoking status. For example, patients 
whose most recent smoking status was “nonsmoker” might have prior codes for “current smoker” 
or “former smoker.” Some “former smokers” had prior codes indicating tobacco use. In short, the 
most recent smoking status was not a reliable indicator of actual smoking history. Other VA 
researchers have used other strategies for addressing these inconsistencies. For example, Jackson 
et al (2015) assigned the most frequently cited status as the smoking status. This strategy yields 
much different proportions of current, former, and nonsmokers than in the current study. In their 
study of 1,844,797 veterans eligible for the MOVE! lifestyle intervention, 23% of whom had 
diabetes at baseline, 36% of participants were classified as current smokers, 31% as former 
smokers, and 34% as never smokers. The “unknown” category was not used. 
5.2 Study Strengths and Limitations  
5.2.1 Study strengths 
 This study is notable for being the first to characterize secular and longitudinal trends in 
body weight in a large, contemporary veteran population from the United States. The dataset 
includes both men and women, with an age range spanning 70 years. The large size of the 
dataset—4.68 million unique patients, with 176 million observations of body weight—ensures 
sufficient statistical power to perform meaningful comparisons between subgroups stratified by 
sex, diabetes status, race, and birth cohort.  
 This study is the first published report on secular trends in body weight in male and 
female veterans with and without diabetes. Because VA data is available to qualified researchers 
at no cost, these datasets could potentially be used to answer other research questions pertaining 
to diabetes, obesity, and healthcare utilization. 
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 This dataset includes a large subpopulation of individuals with elevated body weight, with 
about 25% of the overall population having a body weight between 250-600 lb (113-272 kg); 
hence, this dataset could be used as a starting point to investigate the correlates of extreme 
obesity. There is also a large subpopulation of patients with very high rates of weight 
measurement and primary care utilization, which suggests it may be fruitful as a starting point for 
healthcare resource utilization research in individuals with and without diabetes.  
5.2.2 Study limitations 
Some issues related to data quality require resolution. One male with diabetes recorded a 
total of 10,122 weight observations, an average of 1.8 weight measurements per day throughout 
the 15-year study period. Further investigation is needed to determine whether any of these 
observations are duplicates, or whether such frequent weight measurements can be clinically 
justified.  
Another data quality issue concerns reported race. Evidently the VA’s terminology for 
reporting race varied during 2000-2014. It is probable that unforeseen variants in the raw response 
categories may have contributed to the 3% prevalence of missing subjects in the race-stratified 
analyses. Therefore, caution is warranted when recoding race categories. Gebregziabher et al 
(2011) proposed a 3-way race classification: black, white, and other, where “other” included all 
other races as well as unknown, missing, or patients who declined a response. 
Due to software limitations and time constraints, none of the analyses performed for the 
current study accounted for repeated measures of longitudinal data. 
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5.2.3 Resource limitations 
The most important limitations of this study pertain to the analytical resources available 
through the VINCI platform. Resource limitations, of hardware and software, prevented many of 
the analyses that were planned for this thesis. 
On the hardware side, although 1.1 TB of space appeared to be available on the designated 
Projects drive, only 100 GB of this space could actually be used, and this partition had to be 
shared with several other researchers who were also performing large-scale analytics. Of note, the 
primary analysis file used to answer the questions in Hypothesis 1 occupied 43 GB on disk, and 
required 20-25 minutes to simply load it from the disk into working memory. 
On the software side, the VA’s implementation of the 9.4 release of SAS is missing all of 
the common modeling functions such as PROC REG, GENMOD, and GLIMMIX. Only limited 
regression capabilities have been retained in SAS 9.4. For example, the REG option was used 
within PROC SGPANEL to perform spline fitting and linear modeling with 95% CIs to the 
weight distributions by the year of observation. A number of advanced graphical features used for 
data visualization, such as contour plots and heat-map style probability density plots, have also 
been withheld. These functions are now only available in SAS/Grid. The upgrade from SAS 9.3 
to SAS 9.4 occurred during fall 2015, while the research for this thesis was being conducted. The 
loss of functionality from SAS was wholly unanticipated, and the need for familiarization and 
training on SAS/Grid were outside the scope of the original research protocol.  
SAS/Grid is available in the VINCI platform. This implementation of SAS is specifically 
designed for data mining. Once familiarization and training is completed, this software may 
resolve the resource issues pertaining to memory, speed, and analytical capabilities encountered 
using SAS 9.4 on the very large dataset used in the current study. Alternatively, Stata/MP, the 
multiprocessor implementation of Stata, is also available on VINCI. All implementations of Stata 
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include the same complete set of features as the others—and this includes different regression 
models and graphics. Theoretically, Stata/MP can analyze up to 281 trillion observations, 
although current limitations on hardware memory restrict it to 20 billion observations, with up to 
10,998 variables in the models. As a practical matter, the maximum number of observations on 
VINCI will be limited by the amount of available random-access memory. Further investigation is 
needed to ascertain whether SAS/Grid or Stata/MP would offer the better choice for future 
analyses on this dataset. 
 5.3 Implications of Findings and Conclusions 
 The hypothesis that body weight would increase with time in all groups depended upon 
upon which data are reviewed and how they are analyzed: 
 Secular trends in body weight increased linearly in men and women with and without 
diabetes. The magnitude of the weight increase was similar to that observed in a UK 
population, although in the current study, the females with diabetes weighed more, on 
average, than the men without diabetes. The US veteran population is approximately 10 kg 
heavier than the UK population. 
 Longitudinal trends show increases in some groups, but not others. Body weight increased 
during the study period in all cohorts born since 1950, was stable in cohorts born between 
1940-1949, and decreased in cohorts born before 1940. These trends were similar 
regardless of sex or diabetes status. Trends for men without diabetes resembled those of 
the Normative Aging Study, with higher rates in younger cohorts, but the overall body 
weights are about 10 kg higher.  
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The findings of this study are generally consistent with those of other large, longitudinal 
or cross-sectional studies which also show increases in body weight over time, and faster 
increases in the rate for younger birth cohorts.  
Considering secular trends in body weight, the rates of body weight change in the patients 
without diabetes are higher than the rates of body weight change in the patients with diabetes—
suggesting that future prevalence of diabetes in the VA population will be even higher than it is 
now. Accordingly, urgent efforts are needed to prevent weight gain in the VA population. The 
acceleration of weight increase in the younger cohorts suggests that individuals born after 1975 
should also be targeted for weight loss interventions. 
 An unexpected finding of this study is that patients frequently change how they report 
their smoking history. A novel algorithm based upon the common meaning of the terms current, 
former, and never smoker was used to classify smoking status. This classification method yields 
results that differ substantially from those obtained by selecting the most frequently used status as 
the smoking status. Comparing classification methods would make an interesting potential future 
thesis topic for an MPH student interested in research methods. The smoking dataset may also be 
of interest to research investigating changes in smoking status in the VA healthcare system. 
 Another unexpected finding of this study is that although women with diabetes are 
numerically the smallest subgroup, they account for the highest number of weight observations on 
a per-person basis. This study also identified a large number of primary care “superusers,” with an 
average number of weight observations exceeding 1 visit/week for 15 years. These data need to be 
checked for duplicate records. If they are valid, inquiry could be made to ensure appropriate 
resource utilization within the VA healthcare system: it would be worthwhile to determine why 
these groups have higher utilization than other groups.    
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5.4 Recommendations and Directions for Further Research 
Many researchers are engaged in answering questions pertaining to diabetes and obesity. 
To facilitate future researchers who may search for studies based on this dataset, it is 
recommended that it be given a name related to its purpose and that can be used as a unique 
search string when searching online abstract databases such as PubMed. It is proposed that this 
dataset be named the Veterans Obesity and Diabetes Research Dataset (VODRD) or the Veterans 
Affairs Diabetes and Obesity Research Dataset (VADOR). The latter acronym has the further 
advantages of being easy to remember, pronounce, and spell. 
5.4.1 Further investigation of hypothesis 1 
Survivor bias may account for some of the apparent weight loss in the older cohorts. This 
could be corrected by reanalyzing the data using 3 of the 12 weight periods, where the endpoints 
for the weight periods do not overlap. In this manner, only individuals who were alive and had a 
weight observation in each year of a 12-year period of time would be included in the analysis. 
It may be useful for future research on this dataset to determine whether the regression 
equations described by the coefficients shown in Tables 4.2 and 4.3 are similar. Tests for the 
equality of regression equation coefficients that are robust to the presence of heteroscedasticity 
exist (e.g., Toyoda & Ohtani [1986]). For example, it is clear that the women in this dataset 
generally weigh less than the men, but it is less clear whether there are true differences in the rates 
of weight change by cohort or year of observation. It would be worthwhile to test for 
heteroscedasticity in subpopulations of this dataset that may be selected for future analysis.  
5.4.2 Further investigations of hypotheses 2-4 
Investigation of hypotheses 2-4 will ideally require exclusion of individuals with type 1 
diabetes from the dataset. Although patients with known type 1 diabetes are excluded from 
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enlistment in military service, some veterans may have developed type 1 diabetes after they 
enlisted. The current study attempts to reduce the number of veterans with type 1 diabetes by 
restricting the age range. To further reduce inclusion of patients with type 1 diabetes in future 
analyses, veterans with diabetic ketoacidosis (codes 250.10-13) and BMI < 25 at diagnosis, 
undetectable C-peptide levels, or detectable GAD antibodies should be excluded. 
Consideration should be given to adding variables for treatment facility, height, or BMI to 
the dataset. These variables would permit the effects of geographically related factors to be 
removed from the dataset, and would permit stratification of outcomes by BMI.  
Propensity score matching is another technique meriting consideration. Propensity score 
matching can be used to increase the contrast between two interventions, and is considered the 
next-best thing to a randomized clinical trial.  
To date, there is little consensus on the patient characteristics, behaviors, or treatment 
regimens influencing weight gain with insulin initiation in T2DM. No validated models are 
available to predict the magnitude or direction of weight change with insulin initiation in T2DM. 
Published predictive models of weight gain frequently rely upon variables that would not be 
known at the time of insulin initiation in actual clinical practice. The factors associated with 
extreme (± 20 kg) changes in body weight within the first year of insulin initiation have not been 
identified.  
To further elucidate the magnitude and direction of weight change with insulin initiation 
in T2DM, it may be helpful to: 
 Develop predictive models based on factors that would be known at the time of insulin 
initiation in routine clinical practice, and validate these models against a large dataset. 
Lazarus et al (1998) have previously reported that changes in plasma insulin levels were a 
- 50 - 
significant predictor of change in body weight (P = .026) in the Normative Aging Study. 
Similarly, Kloc (2015) found that both insulin sensitivity and insulin secretion can 
modulate weight gain in a multi-ethnic population of men and women without diabetes. 
 Compare groups of patients at the extremes of weight gain or loss at the same time point 
following insulin initiation to determine whether there are predictable differences in 
weight gain according to disease characteristics, treatment characteristics, behavioral 
factors, or laboratory variables.  
5.4.3 Significance of Aims 2-4 
If this research is performed in its entirety, it will be the first epidemiological study in type 2 
diabetes that will investigate the effects of initiating different antihyperglycemic agents on weight 
change and glycemic control, while controlling for hypoglycemia, physical activity, smoking, and 
other medications associated with weight gain or loss. 
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TABLES 
Table 4.1 Demographic characteristics of study population 
Characteristic Total With Diabetes Without 
Diabetes 
P 
Patients, n (%) 4,680,735 
(100.00)
1,666,346 
(35.60)
2,861,519 
(61.13) 
Sex, n     < .0001
     Male  4,308,893 1,614,688 2,694,205  
     Female 218,972 51,658 167,314  
Race, n     < .0001
     White 3,674,044 1,319,478 2,354,566  
     Black 672,443 274,189 398,254  
     Other 101,914 41,920 59,994  
     Unknown 79,514 30,809 48,705  
     Missing 152,870 56,417 96,453  
Age,a y (mean ± sd)  
    White females 
    White males  70.44 ± 13.44
63.86 ± 13.37
72.48 ± 10.66
57.58 ± 15.91 
70.07 ± 14.26 
< .0001
< .0001
    Black females 
    Black males 63.24 ± 12.84
56.92 ± 10.03
66.66 ± 11.00
50.48 ± 10.87 
62.40 ± 13.27 
< .0001
< .0001
    Other females 
    Other males 65.58 ± 14.53
58.77 ± 12.16
68.88 ± 11.31
52.08 ± 13.93 
64.67 ± 15.74 
< .0001
< .0001
    Unknown 
females 
    Unknown males 
70.03 ± 13.59
63.24 ± 12.77
71.85 ± 11.00
56.40 ± 15.48 
69.93 ± 14.38 
< .0001
< .0001
    Missing females 
    Missing males 68.73 ± 13.85
61.45 ± 12.59
70.99 ± 11.10
55.42 ± 15.11 
68.44 ± 14.66 
< .0001
< .0001
a In 2014. 
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Table 4.2 Proportion of population with and without diabetes, by birth cohort and sex 
Birth 
Cohort 
Total in 
Cohort, n 
With Diabetes Without Diabetes 
F, n M, n Total, n (%) F, n M, n Total, n (%)
1915-1919 90,373 470 25,933 26,403 (29.22) 1761 62,209 63,970 (70.78)
1920-1924 313,198 2640 102,719 105,359 (33.64) 7989 199,850 207,839 (66.36)
1925-1929 426,474 847 161,287 162,134 (38.02) 2007 262,333 264,340 (61.98)
1930-1934 498,854 1920 204,404 206,324 (41.36) 3610 288,920 292,530 (58.64)
1935-1939 403,176 2224 173,115 175,339 (43.49) 3967 223,870 227,837 (56.51)
1940-1944 498,171 3793 214,097 217,890 (43.74) 6640 273,641 280,281 (56.26)
1945-1949 906,017 7331 375,013 382,344 (42.20) 13,237 510,436 523,673 (57.80)
1950-1954 471,326 9899 169,552 179,451 (38.07) 21,295 270,580 291,875 (61.93)
1955-1959 325,181 8826 94,883 103,709 (31.89) 25,387 196,085 221,472 (68.11)
1960-1964 213,660 5971 49,839 55,810 (26.12) 23,448 134,402 157,850 (73.88)
1965-1969 138,318 3187 25,587 28,774 (20.80) 16,765 92,779 109,544 (79.20)
1970-1974 92,998 2153 11,587 13,740 (14.77) 14,112 65,146 79,258 (85.23)
1975-1979 72,146 1424 4424 5848 (8.11) 13,248 53,050 66,298 (91.89)
1980-1984 77,973 973 2248 3221 (4.13) 13,848 60,904 74,752 (95.87)
Totals 4,527,865a 51,658 1,614,688 1,666,346 167,314 2,694,205 2,861,519
a Excludes 152,870 individuals with missing data. Grand total = 4,680,735. DM, diabetes mellitus; F, female; M, male. 
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Table 4.3 Summary of weight statistics by year of observation, females with diabetes 
Wt Year n Mean SD Median Q1 Q3 Min Max
2000 91,493 88.39 19.60 86.64 74.48 100.11 36.29 235.96
2001 125,233 88.70 19.76 86.82 74.84 100.56 36.29 259.19
2002 146,148 89.01 19.98 87.09 74.84 101.10 36.29 264.45
2003 166,959 89.17 20.28 87.09 74.84 101.47 36.29 236.41
2004 188,569 89.38 20.45 87.54 74.84 101.61 36.29 252.43
2005 203,532 89.77 20.72 87.54 75.30 102.06 36.29 249.48
2006 211,196 90.10 20.92 88.04 75.43 102.51 36.29 267.40
2007 222,541 90.23 20.85 88.45 75.66 102.74 36.29 270.00
2008 241,035 90.64 21.11 88.81 75.89 103.10 36.29 268.50
2009 260,055 91.13 21.20 89.13 76.30 103.87 36.29 272.00
2010 257,025 91.35 21.16 89.45 76.52 104.33 36.29 272.00
2011 254,308 91.39 21.11 89.59 76.66 104.33 36.29 264.50
2012 244,067 91.26 21.21 89.36 76.52 104.33 36.29 263.09
2013 231,433 90.96 21.41 89.09 76.20 103.91 36.29 272.16
2014 223,240 88.39 19.60 86.64 74.48 100.11 36.29 235.96
Weight values in kg. Max, maximum; Min, minimum; Q1, 25% quartile; Q3, 75% quartile; Wt Year, year of weight 
observation. 
 
Table 4.4 Summary of weight statistics by year of observation, males with diabetes 
Wt Year n Mean SD Median Q1 Q3 Min Max
2000 2,272,857 96.97 20.08 94.35 83.10 107.96 36.29 272.16
2001 3,196,477 97.16 20.29 94.71 83.10 108.41 36.29 272.16
2002 3,874,723 97.33 20.58 94.80 83.05 108.64 36.29 272.16
2003 4,503,663 97.38 20.88 94.80 83.01 108.86 36.29 272.16
2004 5,022,601 97.45 21.16 94.80 82.92 109.09 36.29 272.16
2005 5,337,943 97.77 21.52 95.26 83.01 109.77 36.29 272.16
2006 5,541,503 98.19 21.91 95.44 83.01 110.22 36.29 272.16
2007 5,686,208 98.60 22.24 95.80 83.19 110.90 36.29 272.16
2008 5,989,368 98.90 21.55 96.16 83.42 111.40 36.29 272.16
2009 6,357,949 99.51 22.66 96.84 83.82 112.13 36.29 272.08
2010 6,254,539 99.79 22.76 97.07 83.92 112.49 36.29 272.16
2011 6,135,949 100.00 22.94 97.30 83.92 112.95 36.29 272.16
2012 5,793,594 100.05 23.08 97.34 83.92 113.04 36.29 272.16
2013 5,486,242 99.91 23.08 97.16 83.82 112.95 36.29 272.16
2014 5,327,701 96.97 20.08 94.35 83.10 107.96 36.29 272.16
Weight values in kg. Max, maximum; Min, minimum; Q1, 25% quartile; Q3, 75% quartile; Wt Year, year of weight 
observation. 
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Table 4.5 Summary of weight statistics by year of observation, females without 
diabetes 
Wt Year n Mean SD Median Q1 Q3 Min Max
2000 169,039 75.76 17.47 73.26 63.05 85.73 36.29 238.46
2001 240,441 76.18 17.65 73.66 63.50 86.18 36.29 261.45
2002 285,739 76.40 17.83 73.94 63.50 86.64 36.29 253.11
2003 330,642 76.68 17.89 74.39 63.78 87.09 36.29 262.18
2004 383,278 76.76 13.53 74.39 63.59 87.09 36.29 254.47
2005 421,487 76.90 18.05 74.39 63.87 87.54 36.29 252.15
2006 451,965 77.20 18.24 74.84 63.96 87.91 36.29 267.00
2007 481,901 77.56 18.47 75.30 64.23 88.45 36.29 268.80
2008 533.047 78.01 18.52 75.75 64.64 88.91 36.29 270.00
2009 591,615 78.62 18.58 76.30 65.20 89.68 36.29 263.00
2010 602,800 78.95 18.62 76.70 65.36 90.13 36.29 265.00
2011 614,770 79.33 18.85 77.11 65.77 90.54 36.29 270.00
2012 586,246 79.93 19.09 77.79 66.09 91.22 36.29 266.00
2013 555,680 80.40 19.26 78.34 66.50 91.99 36.29 268.20
2014 540,531 75.76 17.47 73.26 63.05 85.73 36.29 238.46
Weight values in kg. Max, maximum; Min, minimum; Q1, 25% quartile; Q3, 75% quartile; Wt Year, year of weight 
observation. 
 
Table 4.6 Summary of weight statistics by year of observation, males without 
diabetes 
Wt Year n Mean SD Median Q1 Q3 Min Max
2000 2,511,015 86.16 16.77 84.37 74.84 95.26 36.29 267.44
2001 3,542,600 86.32 16.90 84.46 74.84 95.71 36.29 272.16
2002 4,320,137 86.42 17.07 84.73 74.84 95.71 36.29 272.16
2003 5,092,248 86.36 17.33 84.60 74.84 95.85 36.29 271.70
2004 5,701,941 86.27 17.43 84.37 74.53 95.85 36.29 270.75
2005 6,056,617 86.39 17.69 84.51 74.39 96.16 36.29 272.16
2006 6,286,166 86.71 17.98 84.82 74.57 96.62 36.29 272.16
2007 6,505,014 87.00 18.27 85.09 74.75 97.07 36.29 272.16
2008 6,899,626 87.42 18.53 85.37 74.84 97.52 36.29 272.16
2009 7,435,229 88.09 18.81 86.18 75.30 98.43 36.29 272.16
2010 7,496,083 88.55 18.98 86.50 75.71 99.11 36.29 272.00
2011 7,491,058 88.91 19.21 86.77 75.75 99.66 36.29 272.16
2012 7,027,508 89.12 19.48 87.00 75.75 99.79 36.29 272.00
2013 6,614,960 89.36 19.74 87.09 75.84 100.24 36.29 272.16
2014 6,417,009 89.65 20.06 87.41 75.93 100.70 36.29 272.16
Weight values in kg. Max, maximum; Min, minimum; Q1, 25% quartile; Q3, 75% quartile; Wt Year, year of weight 
observation. 
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Table 4.7 Regression coefficients for secular trends in mean and median body 
weight, by sex and diabetes status, 2000-2014 
a. Regression coefficients as calculated 
Subgroup  
Outcome 
β1 
Slope, lb/y 
β0 
Intercept, lb 
 
R2 P 
Females with DM Mean 
Median 
0.4895 
0.5011 
194.88 
190.58 
0.9046 
0.9103 
< .0001 
< .0001 
Males with DM Mean 
Median 
0.5608 
0.5286 
212.85 
207.25 
0.9316 
0.9260 
< .0001 
< .0001 
Females without DM Mean 
Median 
0.7882 
0.8600 
165.58 
159.94 
0.9691 
0.9671 
< .0001 
< .0001 
Males without DM Mean 
Median 
0.6082 
0.5307 
188.07 
184.36 
0.9118 
0.8941 
< .0001 
< .0001 
DM, diabetes mellitus. 
b. Regression coefficients converted to metric units 
Subgroup  
Outcome 
β1 
Slope, kg/y 
β0 
Intercept, kg 
 
R2 P 
Females with DM Mean 
Median 
0.2220 
0.2273 
88.40 
86.45 
0.9046 
0.9103 
< .0001 
< .0001 
Males with DM Mean 
Median 
0.2544 
0.2398 
96.55 
94.01 
0.9316 
0.9260 
< .0001 
< .0001 
Females without DM Mean 
Median 
0.3575 
0.3901 
75.11 
72.55 
0.9691 
0.9671 
< .0001 
< .0001 
Males without DM Mean 
Median 
0.2759 
0.2407 
85.31 
83.63 
0.9118 
0.8941 
< .0001 
< .0001 
DM, diabetes mellitus. 
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Table 4.8 Regression coefficients for longitudinal rate of change in median body 
weight across birth cohorts 
a. Regression coefficients as calculated 
Subgroup β2 
Acceleration, 
lb2/y 
β1 
Slope, lb/y 
β0 
Intercept, lb 
 
R2 P 
Females with DM 0.0895 –0.2546 –4.1577 0.9517 < .0001
Males with DM 0.0398 0.3362 –4.4998 0.9760 < .0001
Females without DM 0.0127 0.6616 –4.8949 0.9861 < .0001
Males without DM 0.0260 0.4462 –3.9000 0.9881 < .0001
DM, diabetes mellitus. 
 
a. Regression coefficients converted to metric units 
Subgroup β2 
Acceleration, 
kg2/y 
β1 
Slope, kg/y 
β0 
Intercept, kg 
 
R2 P 
Females with DM 0.0406 –0.1155 –1.8859 0.9517 < .0001
Males with DM 0.0181 0.1525 –2.0411 0.9760 < .0001
Females without DM 0.0058 0.3001 –2.2203 0.9861 < .0001
Males without DM 0.0118 0.2024 –1.7690 0.9881 < .0001
DM, diabetes mellitus. 
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FIGURES 
Figure 3.1 Data selection flowchart 
a. Data selection for weight analyses 
 
b. Data selection for Hypotheses 2-4 
 
Dark blue boxes and arrows indicate processes used to prepare data for this thesis. Light blue arrows 
indicate processing to be performed in the future. Green boxes indicate data to be pulled in the future. 
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Figure 3.2 Raw A1C data—cumulative probability 
 
Figure 4.1 Distribution of patients by race, sex, and diabetes status 
 
4,680,735 patients in the entire dataset; 152,870 missing. 
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Figure 4.2 Distribution of unique patients by birth year 
 
4,680,735 patients in the entire dataset; 152,870 missing. 
Figure 4.3 Distribution of weight observations by frequency 
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Figure 4.4 Distribution of weight observations by diabetes status, sex, and birth 
cohort 
  
176,034,543 weight observations for the entire dataset. DM, diabetes mellitus; F, female; M, male. 
Figure 4.5 Distribution of median number of weight observations per patient by 
diabetes status, sex, and birth cohort 
 
176,034,543 weight observations for the entire dataset. DM, diabetes mellitus; F, female; M, male.
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Figure 4.6 Secular trends in mean body weight by year, sex, and diabetes status 
 
DM, diabetes mellitus; F, female; M, male. 
 
Figure 4.7 Distribution of weight observations by sex and year of measurement in 
selected cohorts 
a. 1915-1919 cohort 
 
b. 1945-1947 cohorta 
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c. 1975-1979 cohort 
 
F, female; M, male; resultnumeric, weight (lb). 
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a Because of the large number of individuals with birth years between 1945-1949 (906,017 individuals; 
20,568 females, 885,447 males) caused memory overflow errors in SAS 9.4, a 3-year cohort (1945-1947) 
was computed.  
Figure 4.8 Secular trends in the distribution of weight observations by race, diabetes 
status, and year measured, 1915-1919 birth cohort 
 
a. Patients with diabetes 
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b. Patients without diabetes 
 
 
0, no diabetes; 1, diabetes; resultnumeric, weight (lb); Unkno, unknown. 
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Figure 4.9 Representative longitudinal spline fits for mean body weight with 95% 
CIs, 2000-2014 
 
N, number of unique individuals in cohort; NumWtDate, numeric weight date (x-axis minimum = 2000; 
x-axis maximum = 2014); resultnumeric, weight (lb). Data shown have not been corrected for repeated 
measures. 
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Figure 4.10 Changes in median body weight by birth cohort, 2000 and 2014 
a. Females 
 
b. Males 
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Figure 4.11 Trajectories of rate of change in median body weight by sex, diabetes 
status, and birth cohort, 2000 and 2014 
a. Crude rate—calculated from difference in the median body weight in 2000 and 2014 
 
 
b. Estimated rate—least-squares second-order polynomial 
 
DM, diabetes mellitus; F, female; M, male. 
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Figure 5.1 Baseline differences and longitudinal changes in body weight by birth 
cohort—comparisons with Normative Aging Study (Grinker et al, 1995) 
a. Body weight by birth cohort at study baseline, mean ± SD, kg 
 
 
b. Trends in body weight over 15 years by age by birth cohort 
 
DM, diabetes mellitus. Data for Normative Aging Study from Grinker et al (1995). Legend shows age at 
baseline.  
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APPENDICES 
 
Appendix 1. Clinical Trial Acronyms 
ACCORD, Action to Control Cardiovascular Risk in Diabetes 
ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled 
Evaluation 
CREDIT, Cardiovascular Risk Evaluation in People With Type 2 Diabetes on Insulin Therapy 
ORIGIN, Outcome Reduction with Initial Glargine Intervention 
VADT, Veterans Affairs Diabetes Trial 
 
